Abstract The National Institute for Health and Care Excellence (NICE) invited the manufacturer of ustekinumab (Janssen) to submit evidence for the clinical and cost effectiveness of ustekinumab for the treatment of active psoriatic arthritis (PsA) as part of the Institute's single technology appraisal (STA) process. The Centre for Reviews and Dissemination and the Centre for Health Economics Technology Appraisal Group at the University of York were commissioned to act as the independent Evidence Review Group (ERG). This article provides a description of the ERG review of the manufacturer's evidence submission, and summarises the NICE Appraisal Committee's final guidance (TA340) issued in June 2015. The manufacturer presented evidence on ustekinumab for two patient populations: (1) a tumour necrosis factor-a (TNFa)-inhibitor-naïve population who had not previously received any TNFa inhibitors (biologics); and (2) a TNFainhibitor-exposed population who had previously received at least one TNFa inhibitor. The clinical evidence for ustekinumab was derived from two randomised controlled trials (PSUMMIT 1 and 2), in which a total of 927 patients who had not responded to previous disease-modifying antirheumatic drug therapies received ustekinumab 45 mg, ustekinumab 90 mg, or placebo. These data suggested that ustekinumab is more effective than placebo over 16-24 weeks in terms of both joint and skin response. In the absence of head-to-head comparisons between different biologics (ustekinumab, golimumab, etanercept, adalimumab and infliximab), the manufacturer conducted a network meta-analysis to estimate the relative efficacy of treatments for the TNFa-inhibitor-naïve population. Results of this analysis were marked as academic in confidence and are therefore not reported. For the TNFa-inhibitor-exposed population, the clinical analysis was limited to ustekinumab versus conventional management only, and was based on a subgroup of 180 patients from the PSUMMIT 2 trial. The ERG raised concerns relating to the lack of data on the long-term efficacy of ustekinumab, the limited data available for the exposed population, and the lack of consideration of the sequential use of treatments. Based on the manufacturer's original model, the ERG found ustekinumab to be dominated by golimumab in the anti-TNF-inhibitor-naïve population, and had an incremental cost-effectiveness ratio (ICER) of £29,843/qualityadjusted life-years versus conventional management in the exposed population. The ERG's analyses highlighted the fact that there is significant uncertainty around the model results. In addition, the ERG's exploratory cost-effectiveness analysis, which incorporated the sequential use of TNFa inhibitors, suggested that ustekinumab would not be cost effective if it were used as second-line treatment. The initial NICE recommendations asserted that ustekinumab was not recommended for treating active PsA. However, the manufacturer submitted a post-consultation model that included a Patient Access Scheme (PAS), halving the unit cost of ustekinumab 90 mg to £2147 (the same as a 45 mg dose). The NICE final recommendations were that, dependent on the inclusion of the PAS, ustekinumab is recommended as an option, along or in combination with methotrexate, for treating active PsA in adults only when treatment with TNFa inhibitors is contraindicated but would otherwise be considered, or the person has previously had treatment with one or more TNFa inhibitors, which has failed.
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Introduction
The National Institute for Health and Care Excellence (NICE) is an independent organisation responsible for providing guidance to the National Health Service (NHS) in England and Wales on the use of new and existing health technologies. The NICE's single technology appraisal (STA) process is specifically designed for the appraisal of a single product, device or other technology, with a single indication, where most of the relevant evidence lies with one manufacturer or sponsor [1] . Typically, it is used for new pharmaceutical products close to launch. The evidence for an STA is provided to the NICE by the manufacturer and reviewed by an independent Evidence Review Group (ERG) that is supported by a clinical advisor. The ERG produces a report that provides a critical appraisal of the clinical and cost-effectiveness analysis, as well as some additional analyses [2] . Consultees, clinical experts and patient representatives also provide further information to the NICE Appraisal Committee.
The NICE Appraisal Committee considers all the evidence submitted, including the ERG's independent assessment and testimonies from other experts or stakeholders, to deliberate on whether the technology should be recommended as a clinical and cost-effective use of NHS resources [1] . If the recommendations from the Appraisal Committee are restrictive, an appraisal consultation document (ACD) is produced, which is distributed to consultees and commentators for comment and is made available on the NICE website for wider comment [1] . A second NICE committee meeting is conducted to consider comments on the ACD (if produced), and to make final recommendations for the technology, which are outlined in the final appraisal determination (FAD) document [1] . It is possible for organisations representing patients and carers, healthcare professionals and manufacturers to appeal the final recommendations made for the technology [1] . If no appeals are made against the recommendations in the FAD, or an appeal is not upheld, the final recommendations are issued as an NICE guidance [1] . NHS providers are legally obliged to fund technologies that are recommended in NICE technology guidance, within their licenced indication [1] . This article presents a summary of the ERG's independent critique of the manufacturer's submission to NICE and its role in the subsequent development of the NICE guidance on ustekinumab for the treatment of patients with psoriatic arthritis (PsA).
Full details of the NICE appraisal and the relevant documents can be found on the NICE website [3] .
Decision Problem
PsA is a chronic inflammatory disease closely associated with psoriasis, which affects the skin, joints and soft tissue [4] . PsA is closely associated with psoriasis; 5-7 % of people with psoriasis and 40 % with extensive skin disease have PsA [5] [6] [7] [8] [9] .
Current treatment for PsA typically begins with diseasemodifying antirheumatic drugs (DMARDs) or nonsteroidal anti-inflammatory drugs (NSAIDS), which aim to relieve symptoms, slow disease progression and prevent disability. For patients with active and progressive PsA who have responded inadequately to at least two DMARDs, NICE guidance recommends four alternative licensed tumour necrosis factor-a (TNFa) inhibitors: etanercept, infliximab, adalimumab and golimumab [10, 11] . NICE guidance states that treatment should normally be started with the least expensive TNFa-inhibitor drug (taking into account drug administration costs, required dose and product price per dose) [2] . Although not universal, sequential use of TNFa inhibitors is established practice in the NHS; upon failure of TNFa inhibitors, patients may switch to a different TNFa inhibitor. Failing that, despite the previous lack of efficacy of DMARDs and NSAIDs, patients withdraw back to these suboptimal conventional management strategies (CMS) as there is no current alternative for these patients. Ustekinumab is a monoclonal antibody that acts as a cytokine inhibitor by targeting interleukin (IL)-12 and IL-23 [2] . Ustekinumab, alone or in combination with methotrexate, has a European marketing authorisation for the treatment of active PsA in adult patients when response to previous DMARDs has been inadequate [3] . In addition, ustekinumab has a marketing authorisation for the treatment of moderate to severe plaque psoriasis in adults and adolescent patients from the age of 12 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies, and is currently recommended by the NICE as a treatment for adults with moderate to severe plaque psoriasis [11] . It is expected that both indications for ustekinumab (plaque psoriasis and PsA) would cover approximately 27,000 patients in England and Wales, with 7000 of these being patients with PsA [3] . For PsA, the recommended dose of ustekinumab is 45 mg, administered subcutaneously; an initial dose of 45 mg is followed by a dose 4 weeks later and further doses every 12 weeks after that [2] . Alternatively, for patients weighing over 100 kg, a higher 90 mg dose may be used [2] .
The company (Janssen) submitted evidence to the NICE on the clinical and cost effectiveness of ustekinumab for the treatment of active and progressive PsA in patients who have responded inadequately to previous DMARD therapies. The Centre for Reviews and Dissemination and the Centre for Health Economics at the University of York were commissioned to act as the ERG to critically appraise the manufacturer's submission. The ERG report comprised a critical review of the clinical and cost effectiveness of ustekinumab based on the manufacturer's submission. The aims of the review were to assess whether the manufacturer's submission conformed to the methodological guidelines issued by the NICE, and to assess whether the company's interpretation and analysis of the evidence were appropriate. Additionally, the ERG identified areas in the company's submission requiring clarification, for which the manufacturer provided additional evidence [2] .
Patient Population
The manufacturer presented two scenarios for the use of ustekinumab for PsA, using patient populations at different stages of the treatment pathway.
Patients who had responded inadequately to DMARDs
but not yet progressed to TNFa inhibitors (TNFainhibitor-naïve patients). 2. Patients who had previously received one or more TNFa inhibitors which had failed (due to one of several reasons), and were moving on to treatment with an alternative TNFa inhibitor (TNFa-inhibitorexposed patients).
For each of these populations, the manufacturer considered different comparators.
• For TNFa-inhibitor-naïve patients, ustekinumab was compared with all licensed TNFa inhibitors.
• For the TNFa-inhibitor-exposed patients, ustekinumab was compared with conventional management only.
Critique of Patient Population
The ERG noted that neither of the manufacturer's scenarios fully reflected UK clinical practice, where up to four TNFa inhibitors can be administered in (no fixed) sequence. The TNFa-inhibitor-naïve scenario considers the specific case of ustekinumab as an alternative to first-line TNFa-inhibitor treatment. In the TNFa-inhibitor-exposed scenario, use of conventional management as the sole comparator implies that patients have exhausted all TNFa-inhibitor options; therefore, this scenario represents the specific case of ustekinumab as an end-line treatment option, after a sequence of up to four TNFa inhibitors has been tried and failed. As such, the manufacturer did not evaluate the effectiveness of ustekinumab as an alternative to a secondor third-line TNFa inhibitor, which is also a relevant comparison for patients being treated with sequential TNFa inhibitors. The manufacturer's analysis therefore only addresses a restricted part of the decision problem, placing ustekinumab either at the beginning or end of the TNFa-inhibitor treatment sequence.
Clinical Evidence
The manufacturer conducted a systematic review to identify relevant evidence on the clinical effectiveness of ustekinumab for the treatment of active and progressive PsA [2] . The majority of evidence on the efficacy of ustekinumab was derived from two randomised controlled trials (RCTs; PSUMMIT 1 and PSUMMIT 2), identified in this review [12, 13] . Across both trials, a total of 927 patients who had not responded to previous DMARD therapies were randomly assigned to receive ustekinumab 45 mg, ustekinumab 90 mg, or placebo, which is assumed to equate to CMS. The PSUMMIT 2 trial included a subgroup of 180 patients who had previously received at least one TNFa inhibitor [12] . In both trials, at week 16, patients who had not responded to active treatment entered a blinded 'earlyescape', in which nonresponders in the conventional management arm received ustekinumab 45 mg, and nonresponders in the ustekinumab 45 mg arm received the higher 90 mg dose [12, 13] . At week 24, all remaining patients in the placebo group received ustekinumab 45 mg [12, 13] .
The primary outcome of both trials was treatment response defined as a 20 % or greater improvement in joint condition according to the American College of Rheumatology assessment criteria (ACR20) at 24 weeks [12, 13] . Secondary outcomes included response rates for ACR50/ 70, Psoriasis Area and Severity Index (PASI) 75/90, the Disability Index of the Health Assessment Questionnaire (HAQ-DI) and radiographic progression assessed by changes in modified van der Heijde-Sharp score (vdH-S) and PsA Response Criteria (PsARC) [12, 13] .
Data from the PSUMMIT trials suggest that for TNFainhibitor-naïve and TNFa-inhibitor-exposed patients, ustekinumab is more effective than placebo over 16-24 weeks in terms of both joint (ACR 20/50/70, PsARC) and skin (PASI 75) response (see Table 1 ) [12, 13] . In response to the ERG's query, the manufacturer provided additional data on outcomes up to 52 weeks, which showed that the benefits seen at 16-24 weeks are likely to persist for at least 52 weeks for the TNFa-inhibitor-naïve population.
Evidence from the PSUMMIT 2 trial subgroup showed that overall response rates were lower for the TNFa-inhibitor-exposed population compared with the naïve population, but there was no statistically significant difference in the efficacy of ustekinumab between TNFa-inhibitornaïve and exposed patients [12] . No obvious difference was observed between ustekinumab doses or interactions between dose and prior TNFa-inhibitor exposure. Treatment effects were not significantly different for the 45 mg and 90 mg doses of ustekinumab (Table 1 ).
In the absence of head-to-head comparisons of the relative efficacy between different biologics (ustekinumab, golimumab, etanercept, adalimumab and infliximab), the manufacturer conducted a network meta-analysis (NMA) incorporating nine placebo-controlled RCTs to estimate the relative efficacy of the five relevant biologics and conventional management in the TNFa-inhibitor-naïve population. Separate networks were constructed for three outcomes (PASI 75, PASI 90 and PsARC) and across two time points (12-16 weeks and 24 weeks). As outcomes at 24 weeks only were available for ustekinumab, these were assumed equal to the outcomes at 12-16 weeks for the NMA. The results of the NMA were marked as academic in confidence and therefore the results cannot be reported here.
With the exception of a slightly higher proportion of injection site reactions for ustekinumab 90 mg observed in the PSUMMIT trials (1 % 90 mg vs. 0.6 % 45 mg vs. 0.4 % placebo), the included trial data did not suggest any obvious excess in adverse events for ustekinumab-treated patients [12, 13] .
Critique of the Clinical Evidence
The PSUMMIT trials from which evidence on the efficacy of ustekinumab was derived were of adequate All data are expressed as a proportion of participants meeting the criteria unless otherwise indicated Placebo is assumed to equate to CMS 95 % CIs for RR results were marked as confidential in the manufacturer's response to clarifications and therefore could not be reported
TNFa tumour necrosis factor-a, ACR American College of Rheumatology, PsARC psoriatic arthritis response criteria, PASI Psoriasis Area and Severity Index, RR relative risk, CMS conventional management strategies, CIs confidence intervals methodological quality. The results obtained from these trials are likely to be valid, and indicate that ustekinumab is a more effective treatment than placebo over 16-24 weeks, and that these benefits are likely to persist for at least 52 weeks. However, the interruption of the placebo-controlled phase at week 16, and the termination of the controlled phase altogether at 24 weeks, mean that the trials only provide a brief comparison for a chronic condition such as PsA. No data were available on longer-term radiographic progression.
For the TNFa-inhibitor-exposed population, the analysis was based on a subgroup of 180 patients from the PSUMMIT 2 trial who had received a varied number of prior TNFa inhibitors [12] . Thus, data for participants who could be considered truly 'TNFa-inhibitor refractory' (i.e. having exhausted all biological treatments sequentially and for whom conventional management would be the appropriate comparator) are sparse (numbers confidential and therefore cannot be reported). In addition, it was unclear which biologic treatments these patients had received and the relative efficacy of the treatments when given in the different positions within the sequence.
Several of the trials included in the NMA (including the PSUMMIT trials) included participants who had never received prior DMARD therapy and, where reported, the mean number of prior DMARDs was typically fewer than two. This suggests that the NMA population may be less severe than that routinely considered for biologic treatment in practice (where patients are required to have not responded to two or more prior DMARDs). Nevertheless, the trials were broadly similar in terms of disease severity and functional status, therefore the NMA results should be valid for the population assessed.
PsARC and PASI response rates used for ustekinumab in the manufacturer's NMA were derived from a subset of patients from the PSUMMIT trials who were treated according to a strict weight-based dosing regimen. That is, data were only used on participants in the 45 mg arm who weighed less than 100 kg, and participants in the 90 mg arm who weighed more than 100 kg. This resulted in a significant amount of data being discarded, and the ERG believed that this strict weight-based dosing does not fully reflect the license for ustekinumab since all patients may commence treatment on the 45 mg dose, regardless of weight. The ERG conducted a sensitivity analysis for the TNFa-inhibitor-naïve population, using the full intentionto-treat (ITT) population. In general, the results were fairly similar across both the weight-based and full ITT populations.
Cost-Effectiveness Evidence
The manufacturer constructed a combined decision-tree and Markov model to compare adalimumab, etanercept, infliximab, golimumab and ustekinumab versus conventional management for TNFa-inhibitor-naïve patients and to compare ustekinumab with conventional management only for TNF-a-inhibitor-exposed patients. A time horizon of 52 years was used. The decision-tree structure is presented in Fig. 1 [2] , and the Markov model structure is presented in Fig. 2 [2] .
The key inputs in the model were PsARC response rates, HAQ change for responders and nonresponders, and PASI score changes. This information is not presented here as a significant portion is academic in confidence and therefore redacted.
Patients achieving an initial PsARC response at 12 weeks for TNFa inhibitors, and 24 weeks for ustekinumab, were considered to be responders and continued active treatment. Nonresponders were withdrawn to conventional management. Patients remaining on active treatment were subject to a constant withdrawal rate to account for long-term treatment discontinuation. Treatment effectiveness was modelled as an improvement in PASI and HAQ scores from baseline, which were both secondary outcomes in the PSUMMIT trials. Upon withdrawal to conventional management, HAQ and PASI scores rebounded to baseline levels, with HAQ scores assumed to ERG Evidence Review Group, TNFa tumour necrosis factor-a, QALYs quality-adjusted life-years, ICER incremental cost-effectiveness ratio, CMS conventional management strategies gradually deteriorate over time, according to the 'natural history' of HAQ. For the TNFa-inhibitor-naïve population, PASI response rates were obtained from the manufacturer's NMA, and HAQ score changes were derived from a previously conducted NMA [14] . For the TNFa-inhibitor-exposed population, effectiveness estimates were derived from the PSUMMIT 2 exposed subgroup [12] . If a patient achieved a PASI response great enough to continue treatment, a fixed improvement in PASI score based on PASI response was assumed. Conventional management was assumed to have no impact on skin symptoms. It was also assumed that, for people who withdraw from biological therapy, the PASI score would rebound to a score based on the effect of conventional management (rather than the baseline score).
Patient quality-adjusted life-years (QALYs) and health state costs were estimated as a function of HAQ and PASI scores. HAQ-and PASI-related costs were based on estimates used in the previous manufacturer's submission for golimumab [14] . Medical resource use requirements for patients receiving ustekinumab were assumed to be the same as for patients on other biologics. Resource use costs were taken from NHS reference costs [15] , and TNFainhibitor acquisition costs were derived from the British National Formulary [16] . Each 45 mg unit of ustekinumab costs £2147. Drug administration costs were only applied to infliximab, which requires intravenous infusion at hospital. Detailed deterministic and probabilistic sensitivity analyses were undertaken.
Minor errors in the manufacturer's original model and its inputs were corrected by the ERG and agreed by the manufacturer, which included recalculating the baseline HAQ and PASI values.
For the TNFa-inhibitor-naïve population, the ERGcorrected model found that ustekinumab was dominated by golimumab (with golimumab being less costly and more effective than ustekinumab [3] . The incremental cost-effectiveness ratio (ICER) for ustekinumab versus conventional management was £23,508/QALY gained ( Table 2) .
For the TNFa-inhibitor-exposed population, the ERGcorrected model found that the ICER for ustekinumab versus conventional management was £29,843/QALY gained (see Table 3 ). These results were very similar to the manufacturer's original base-case results.
Results of the sensitivity analysis, for both the TNFainhibitor-naïve and TNFa-inhibitor-exposed population, Fig. 1 Decision-tree structure. PASI Psoriasis Area and Severity Index, tx treatment, PsARC psoriatic arthritis response criteria showed that the results were particularly sensitive to the HAQ natural history rate of deterioration, the time horizon used and whether the treatment response was assessed at 12 or 24 weeks.
Critique of the Cost-Effectiveness Evidence
In general, the ERG considered the manufacturer's economic evaluation to be of good quality, using an appropriate structure and meeting the requirements of the NICE reference case. However, the ERG had concerns about several assumptions used in the model, as discussed below.
Health Assessment Questionnaire Rebound
A key assumption in the model is that upon treatment discontinuation, patients' HAQ score rebounds to the baseline level, and subsequently deteriorates in line with the natural progression of HAQ. The manufacturer's model allowed for a sensitivity analysis in which HAQ was assumed to rebound to the point where patients would have been had they remained on conventional management, i.e. the point on the natural progression line for patients who received no biologic treatment. This is considered by the ERG to be an important scenario as it represents a 'worst-case scenario' for HAQ rebounding. Although the model allowed for this analysis, the results for this scenario were not reported in Fig. 2 Markov model structure. PsARC psoriatic arthritis response criteria, PASI Psoriasis Area and Severity Index, conv. mgmt conventional management, tx treatment ERG Evidence Review Group, TNFa tumour necrosis factor-a, QALYs quality-adjusted life-years, ICER incremental cost-effectiveness ratio, CMS conventional management strategies the manufacturer's submission. This analysis was therefore re-run by the ERG. Ustekinumab remained dominated by golimumab but the ICER versus conventional management increased from £23,508/QALY (base-case) to £41,500/ QALY. Similarly for the TNFa-inhibitor-exposed population, assuming HAQ rebounds to the natural progression point resulted in the ICER for ustekinumab versus conventional management increasing from £29,843/QALY to £52,408/QALY. There is also uncertainty as to the point and speed at which HAQ levels may be expected to rebound to the baseline level. The manufacturer assumed that HAQ would immediately rebound to the baseline score upon treatment discontinuation. It may be that HAQ scores would gradually worsen over a period of time prior to treatment withdrawal, especially in cases of withdrawal due to waning efficacy. The model did not easily facilitate further exploration of the issue; however, as this would decrease the effectiveness of the TNFa inhibitor, it is expected that this scenario would again increase the ICERs, making all of the biologic treatments less cost-effective options.
Tumour Necrosis Factor-a (TNFa)-Inhibitor-Exposed Population: Evidence Review Group (ERG) Exploratory Analysis
The manufacturer suggested that ustekinumab provides a novel treatment option when TNFa-inhibitor treatment has failed using conventional management as the comparator [2] . However, although the manufacturer's model implicitly assumed that the TNFainhibitor-exposed patients had exhausted all TNFa-inhibitor treatment options and have no choice but to revert to nonbiologic treatments, their model used evidence derived from a trial population who had experienced TNFa inhibitors but who had not necessarily failed them as a class. It was clear from the PSUMMIT 2 patient characteristics that the subgroup of exposed patients were not all patients who have exhausted TNFa-inhibitor treatments [12] . Using conventional management as the only comparator is therefore only appropriate for a subgroup of this subpopulation. The ERG performed an exploratory analysis where golimumab, adalimumab or etanercept were used as first-line treatments, and ustekinumab was compared with the other TNFa inhibitors as second-line treatments. This analysis was based on some additional ERG exploratory analyses undertaken in a previous submission [10] , which assumed patients were receiving second-line treatment due to failure of first-line treatment as a result of either lack of efficacy or adverse events. Based on clinical literature on the relative risk of not responding to a second biologic drug compared with not responding to a first-line drug, four sets of equations that adjusted the response and withdrawal rates for TNFa-inhibitor-exposed patients were estimated [17, 18] . These adjusted rates were used to estimate costs and QALYs for ustekinumab when adalimumab, etanercept or infliximab were the failed first-line TNFa inhibitors used.
Whilst observational evidence suggests diminishing response rates and treatment persistence associated with the sequential use of TNFa inhibitors, there is no robust evidence for the relative efficacy of ustekinumab and TNFa inhibitors when used as second-or later-line therapy [10] . The NMA results suggest that most TNFa inhibitors are more efficacious than ustekinumab in the TNFa-inhibitor-naïve population, and no evidence is presented to suggest that the postulated reduction in efficacy of second-, third-, or fourth-line TNFa inhibitors would drop below the level of efficacy observed for ustekinumab in TNFa-inhibitor-exposed patients.
This scenario is still not fully reflective of current practice in the UK (in that third-and fourth-line treatment options were not included); however, it does allow for the appropriate comparators for ustekinumab in a TNFa-inhibitorexposed (rather than exhausted) population to be considered. For all of these scenarios, ustekinumab, as a second-line treatment, was either dominated by other treatments or was not cost effective at a £30,000/QALY threshold. However, it should be noted that these results were subject to significant uncertainty due to limitations in the analysis and the strong assumptions made (which include the assumptions that second-line treatment would have the same probabilities of a PASI 75 response as in first-line treatment; that resource use estimates would be unchanged; and the more up-to-date clinical estimates provided in the manufacturer's submission would not be used).
A shortcoming of both the manufacturer's submission and the ERG report is that neither analysis addressed where ustekinumab would fit in the sequence of TNFa inhibitors, and neither explored all possible options. The manufacturer assumed that the effectiveness data collected in the PSUMMIT 2 trial reflects end-of-line effectiveness, and the ERG exploratory analysis assumed the effectiveness data reflects second-line effectiveness [12] . Neither assumption is robust; however, the ERG exploratory analysis highlights the issues around the sequencing of TNFa-inhibitor treatments that should be taken into consideration in future research.
The following assumptions were subjected to further sensitivity analyses by the ERG but were not found to have any meaningful impact on the results:
• using data from the PSUMMIT trials based on ITT populations, instead of restricted-weight populations, in order to reflect how ustekinumab would be used in practice; • including data on HAQ change from baseline per PsARC responder/nonresponder for ustekinumab from the weight-based PSUMMIT results instead of using the HAQ score changes from a previous NMA [17] ; • reducing the time horizon from 52 years to 40 years, to stay in line with previous submissions and enable comparisons [10, 11] ; • response to treatment in terms of PsARC response was assumed to occur at week 12, in line with previous submissions to enable comparisons [10, 11] .
Conclusions of the ERG Review

TNFa-Inhibitor-Naïve Population
Trial evidence demonstrates that ustekinumab is more effective than placebo over 16-24 weeks in terms of both joint (ACR 20/50/70, PsARC) and skin (PASI 75/90) response, and these benefits are likely to persist for at least 52 weeks. However, when compared with TNFa inhibitors for first-line biologic treatment, results of the manufacturer's cost-effectiveness analysis indicate that ustekinumab is not a cost-effective alternative to current treatment options. Pairwise comparisons against conventional management found that golimumab, etanercept and adalimumab all had lower ICERs than ustekinumab. The ERG's clarifications, corrections and additional analyses did not substantially change these results but did highlight the high levels of uncertainty in the analysis.
TNFa-Inhibitor-Exposed Population
Trial evidence suggests there is no convincing evidence of a substantial difference in the efficacy of ustekinumab between TNFa-inhibitor-exposed patients and patients who have not received any prior TNFa-inhibitor treatment. Any benefit observed may be an artefact of the small number of patients in the analysis. This evidence cannot be presented as the NMA was academic in confidence. The ERG believed there were issues around the manufacturer's analysis of the TNFa-inhibitor-exposed population and the lack of consideration given to treatment sequencing and the use of ustekinumab as a second-or third-line treatment option, which may more appropriately reflect how ustekinumab would be expected to be used in UK clinical practice within the current sequencing approach to TNF inhibitors.
The ERG's exploratory cost-effectiveness analysis, which incorporated the sequential use of TNFa inhibitors suggested that ustekinumab would be dominated or have an ICER above the NICE £30,000 upper threshold, regardless of the reason for the first-line treatment failure or which TNFa-inhibitor treatment was used as the first-time line treatment.
Key Methodological Issues
Clinical Effectiveness
The main areas of uncertainty in terms of clinical efficacy and drug safety were as follows:
• the lack of data on longer-term efficacy and safety of ustekinumab; • the efficacy of ustekinumab in TNFa-inhibitor-exposed patients compared with second-and third-line TNFa inhibitors. A properly powered trial of ustekinumab versus TNFa-inhibitor therapy is required. Any such trial should clearly distinguish between prior TNFainhibitor exposure and TNFa-inhibitor class failure in its selection of participants so that reliable subgroup analyses could be undertaken.
Cost Effectiveness
The main areas of uncertainty in terms of cost effectiveness were as follows.
• The natural history of HAQ for patients receiving conventional management.
• Rebound to HAQ on withdrawal from treatment.
Further evidence is required to identify which scenario is most likely to reflect clinical reality.
• The cost effectiveness of ustekinumab in TNFainhibitor-exposed patients compared with second-and third-line TNFa inhibitors. Whilst the ERG exploratory analysis suggests that ustekinumab would not be cost effective compared with alternative TNFa inhibitors in this instance, this analysis was based on strong assumptions.
The decision question that has not been addressed by either the manufacturer or the ERG is where ustekinumab fits within sequential treatment TNFa inhibitors, and this is an area of further research that needs to be undertaken.
Consideration of All Available Evidence
The NICE Appraisal Committee reviewed the data available on the clinical and cost effectiveness of ustekinumab, and considered the evidence presented in the manufacturer's submission, ERG report and a range of additional sources, including clinical experts, related health professionals, patient representatives, and professional and specialist groups. It also took into account the effective use of NHS resources.
Preliminary Guidance
The preliminary NICE recommendations, recorded in the ACD, were that ustekinumab was not recommended for treating active PsA [2] .
Manufacturer's Response to the Appraisal Consultation Document Consultation
The manufacturer submitted a response to the consultation document, which included some minor corrections to the original submission, in addition to the corrections made within the ERG report and the assumption that only a 45 mg dose was available. This response document did not change the conclusions made in the ACD.
Final Guidance
The final NICE recommendations, recorded in the final guidance to the NHS (TA313), were that ustekinumab was not recommended for treating active PsA [2] ; however, the manufacturer subsequently submitted a revised analysis, which led to a revision of the NICE recommendations as outlined in TA340.
Manufacturer's Post-Consultation Model
Following the publication of the FAD (TA313), the manufacturer submitted a revised economic analysis based on its post-consultation model. The manufacturer updated their model to incorporate some of the Committee's requested amendments: the effect of conventional management on skin symptoms was modelled in the same way as the effects of biological drugs in the original model, where a fixed improvement in PASI score based on PASI response was assumed. It was also assumed that, for people who withdraw from biological therapy, the PASI score would rebound to a score based on the effect of conventional management (rather than the baseline score). This post-consultation model also included a Patient Access Scheme (PAS). As reported in the FAD, the PAS consisted of a halving of the unit cost of ustekinumab 90 mg to £2147, the same cost as a 45 mg dose [2] . The ERG considered that the new assumption on the effect of conventional management on skin symptoms was appropriate.
A sequential treatment scenario analysis was also presented based on the ERG exploratory analysis which allowed ustekinumab to be compared with second-line TNFa-inhibitor treatment following failure of first-line TNFa-inhibitor treatment.
ERG Critique of the Manufacturer's PostConsultation Model
The ERG reviewed the manufacturer's resubmitted postconsultation model, and conducted another analysis incorporating two more of the NICE committee's preferred assumptions that could feasibly be implemented. These were using a 40-year time horizon and assessing response at 24 weeks for both ustekinumab and conventional management. During this rapid review of the post-consultation model, the ERG identified a number of errors in the manufacturer's model and these were corrected. These ERG corrections, the inclusion of the NICE committee's preferred assumptions, as well as the inclusion of the PAS price for the 90 mg dose of ustekinumab, all had an effect on the final cost-effectiveness estimates. Whilst the inclusion of the NICE committee's preferred assumptions increased the ICERs, both the ERG corrections and the inclusion of the PAS price for the 90 mg dose of ustekinumab decreased the ICERs. The results of the manufacturer's post-consultation model and the ERG's alternative model (which incorporated the additional two NICE committee preferred assumptions) are presented in Table 4 . Both of these results incorporated the PAS price for the 90 mg dose and the ERG's corrections of the identified errors. While the manufacturer presented results for TNFa-inhibitor-naïve patients, TNFa-inhibitor-exposed patients, and a sequential model, Table 4 presents the results for four populations highlighted in the TA guidance 313 [2] .
The appropriate comparators for TNFa-inhibitor-naïve patients who are able to have all TNFa inhibitors, including ustekinumab (i.e. not contraindicated) were the other TNFa inhibitors. When compared with the other inhibitors, ustekinumab was extendedly dominated in both the manufacturer's and the ERG's models.
The appropriate comparator for TNFa-inhibitor-naïve patients who cannot have TNFa inhibitors (i.e. contraindicated) was conventional management. In the manufacturer's model, the ICER was estimated to be £17,906. When the ERG included the additional two Committee preferences, this increased the ICER to £23,938.
The appropriate comparator for TNFa-inhibitor-exposed patients who did not respond to their first TNFa inhibitor due to lack of efficacy or adverse reactions, and were now receiving ustekinumab, was the other TNFa inhibitors as second-line treatments. This analysis used the sequential model in the ERG's exploratory analysis. In the manufacturer's model, the ICER was estimated to be £20,175. When the ERG included the additional two Committee preferences, this increased the ICER to £28,281.
The appropriate comparator for TNFa-inhibitor-exposed patients who did not respond to all TNFa inhibitors as a class, and were now receiving ustekinumab, was CMS. Again, this analysis used the sequential model in the ERG's exploratory analysis. In the manufacturer's model, the ICER was estimated to be £20,068. When the ERG included the additional two Committee preferences, this increased the ICER to £27,307.
National Institute for Health and Care Excellence Final Guidance
On considering the responses to the preliminary guidance and the manufacturer's PAS submission, the Committee updated the original FAD for ustekinumab [2] . The final FAD states: ''Ustekinumab is recommended as an option, alone or in combination with methotrexate, for treating active PsA in adults only when:
• Treatment with TNFa inhibitors is contraindicated but would otherwise be considered, or • The person has had treatment with one or more TNFa inhibitors.
Ustekinumab is recommended only if the company provides the 90 mg dose of ustekinumab for people who weigh more than 100 kg at the same cost as the 45 mg dose, as agreed in the patient access scheme.''
Interpretation of the Guidance
The sequential use of TNFa inhibitors in the UK was a much-discussed issue within this appraisal. Although not universally available, it was agreed within the Appraisal Committee meetings that sequential treatment with TNFa inhibitors is administered in the UK. The appraisal for ustekinumab differs from previous appraisals of TNFa inhibitors in that the use of the intervention as a second-, third-or fourth-line treatment for PsA was explicitly considered. This presented a new challenge to the ERG to critique the appraisal, not just in terms of first-line treatment but also for subsequent sequential treatment with TNFa inhibitors. The literature around sequential use of TNFa inhibitors was limited and the challenge was to model the sequential use of TNFa inhibitors in a credible way.
The final recommendation for ustekinumab indicates that unless a patient is contraindicated to other treatment options, ustekinumab should be reserved for second-line treatment in patients with PsA. 
